^
    Back
    Association details:
    Biomarker:MYC rearrangement
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:Breyanzi (lisocabtagene maraleucel) (CD19-targeted CAR-T immunotherapy)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

    Excerpt:
    ...DLBCL cohort (no longer enrolling): DLBCL, not otherwise specified (NOS; includes transformed DLBCL from indolent histology [tDLBCL]), high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements...
    Trial ID:
    TRANSCEND-NHL-001
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Blood
    Title:

    Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

    Excerpt:
    Pts aged ≥18 yrs in the DLBCL cohort had R/R DLBCL not otherwise specified (NOS; including transformed from any indolent lymphoma), high-grade B cell lymphoma (HGBCL) with MYC and BCL2 and/or BCL6 rearrangements,...Liso-cel demonstrated durable clinical activity with a favorable safety profile in this large study of CAR T cell therapy in R/R large B cell NHL.
    DOI:
    10.1182/blood-2019-127508